Metoprolol Retard Terapia

Metoprolol Tartrate, the active ingredient in Metoprolol Retard Terapia, is a beta blocker presented as an oral tablet for oral use. It is used to lower blood pressure, relieve angina and improve outcomes after heart attacks and in chronic heart failure. GNH USA supplies Metoprolol Retard Terapia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Tartrate acts on the cardiovascular system to control blood pressure and heart workload. - Hypertension: reduces systolic and diastolic pressure, helping prevent stroke and organ damage. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion. - Post‑myocardial infarction: lowers risk of recurrent infarction and improves survival. - Chronic heart failure: improves ventricular function and reduces hospitalization rates.

Metoprolol Tartrate may cause a range of adverse reactions.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: light‑headedness, especially when standing quickly. - Bradycardia: slower than normal heart rate. - Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to fainting or shock. - Bronchospasm in patients with asthma or chronic obstructive lung disease.

Before prescribing Metoprolol Tartrate, clinicians should consider several safety factors. - Blood pressure monitoring: ensure adequate control without excessive hypotension. - Cardiac function assessment: evaluate for heart block or severe bradycardia. - Concomitant beta‑blocker use: avoid duplicate therapy that may amplify effects. - Respiratory caution: use carefully in patients with asthma or COPD. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metoprolol Tartrate can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive cardiac depression. - Calcium channel blockers (verapamil, diltiazem): risk of severe bradycardia and AV block. - Antidiabetic agents: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): increase metoprolol plasma levels. - NSAIDs: may reduce antihypertensive effect, requiring BP monitoring.